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M

yotonic dystrophy (DM) is an autosomal dominant,
multisystem myopathic disorder associated with two
loci, DM1 and DM2 (1). Only DM1 is associated with
severe symptoms in the newborn period, a form known as
congenital DM (CDM). DM1 is the result of a CTG trinucleotide repeat expansion found rather uniquely in an
intron (noncoding) portion of a gene associated with the
dystrophia myotonica protein kinase gene. This gene is
located on chromosome 19q13.3 and the mutant repeat
expansion causes abnormal splicing of a number of premessenger RNA transcripts, leading to a phenotype with muscle
weakness, myotonia, cardiac rhythm disturbance and cataracts as the main symptoms (2). A DM phenotype is commonly observed when the CTG repeat size exceeds 50;
however, the repeat size in those with CDM is often much
larger, typically greater than 1000.
CDM occurs as a result of the process of genetic anticipation. In this process, the unstable trinucleotide repeat
(almost always transferred from the mother) can expand
during gametogenesis, which is associated with an earlier
onset and more severe disease manifestations in the affected

oBJeCtiF : Décrire les symptômes néonatals, les troubles développementaux et les morbidités médicales multisystémiques chroniques des
patients atteints de dystrophie myoclonique congénitale (DMC)
inscrits dans le National Registry of Myotonic Dystrophy des États-Unis,
un programme d’autodéclaration de cette maladie tenu depuis 2002.
Le registre est comparé au Programme canadien de surveillance pédiatrique sur la DMC.
MÉtHodoloGie : Les chercheurs décrivent les cas génétiquement
confirmés de DMC démontrant des symptômes pendant les quatre
premières semaines de vie. Les patients (ou la personne qui s’occupe
d’eux) et les médecins ont rempli le sondage au départ, puis tous les ans
par la suite.
RÉSultAtS : Vingt et un patients (13 garçons et huit filles) de trois
à 24 ans étaient inclus. L’expansion du triplet de nucléotides CTG se
situait entre 940 et 2 100 répétitions. Les morbidités gastro-intestinales,
cardiaques et liées à la pneumonie étaient les plus courantes. On n’a
constaté aucun décès.
ConCluSionS : Le registre des États-Unis est une source précieuse
de recherche clinique sur les personnes ayant une DMC, mais par rapport au Programme canadien de surveillance pédiatrique, il comporte
certaines limites.

infant. The symptoms of CDM are often displayed in utero
as decreased fetal movements and polyhydramnios (3).
Symptoms observed more consistently at birth include
hypotonia, weakness, feeding difficulties and mechanical
respiratory failure requiring intubation and ventilation (4).
CDM is associated with significant morbidity in the newborn period, and mortality rates as high as 40% have been
reported (4).
The prevalence of CDM is estimated to be one per 3500 to
16,000 individuals (5,6); however, no published populationbased incidence studies exist. As well, the lack of a clear and
consistent case definition of CDM in the medical literature
further complicates efforts to accurately record clinical characteristics and outcomes in this population. Two populationbased studies are currently being conducted with these issues
in mind, but with different objectives. The first study, which
is examined in the present article, is maintained by the
University of Rochester Medical Center (New York, USA),
The National Registry of Myotonic Dystrophy and
Facioscapulohumeral Muscular Dystrophy Patients and
Family Members (hereon referred to as the United States
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AiM: To describe the neonatal symptoms, developmental problems
and chronic multisystem medical morbidities of congenital myotonic
dystrophy (CDM) patients registered in the United States National
Registry of Myotonic Dystrophy – a disease-specific, self-report program maintained since 2002. Comparisons with the Canadian
Paediatric Surveillance Program for CDM are highlighted.
MetHodS: Genetically confirmed cases of CDM demonstrating
symptoms in the first four weeks of life are described. Patients (or their
caregivers) and physicians completed survey information at baseline
and annually thereafter.
ReSultS: Twenty-one patients were included (13 male and eight
female), ranging from three to 24 years of age. The CTG trinucleotide
repeat number ranged from 940 to 2100. Gastrointestinal, pneumonia
and cardiac morbidities were most common. No deaths were noted.
ConCluSionS: The United States Registry is a valuable resource
for clinical research on patients with CDM; however, in contrast with
the Canadian Paediatric Surveillance Program, some limitations are
identified.

la dystrophie myotonique congénitale dans un
registre national de dystrophie myotonique

CDM in the US Registry

MetHod
The US Registry recruits patients from across the US using
a variety of methods. These recruiting methods include the
registry’s website, the Rochester neuromuscular clinic, muscular dystrophy association clinics, mailings to neurology
groups and individual physicians, support groups and diseaserelated publications. Enrollment is voluntary.
The US Registry consists of information from both the
patient and his/her physician. When enrolled, patients provide medical records and are asked to complete a survey
known as the patient information form (PIF). This survey is
available online through the registry’s website (www.urmc.
rochester.edu/nihregistry/). A similar survey is mailed annually to all patients and serves to track any changes in their
condition. The survey information can be grouped into
12 overall categories. These categories include the following: information about diagnosis, use of assistive devices,
signs and symptoms, broken bones and surgery, medications,
allergies, sleep problems, other medical problems, treatments or counselling, occupation and employment, education and ethnicity/race. A physician checklist (PCL)
collects information to confirm the diagnosis and assign a
DM classification. It also provides overlap of information
pertaining to initial symptoms, method(s) of diagnosis and
family members affected, which also verifies the clinical
information reported by the patients.
Because CDM1 and childhood DM1 patients were grouped
together in the US Registry database, the following inclusion
criteria were used to identify cases of CDM: symptoms evident within the first four weeks of life, and a confirmed genetic diagnosis of DM1 and/or a first-degree relative with
Paediatr Child Health Vol 15 No 8 October 2010

genetic confirmation. Both the PIF and the PCL were used to
exclude noneligible patients, with the PCL taking priority
over the PIF. Anonymous data of 45 CDM and childhood
DM1 patients were reviewed. The application of the inclusion criteria outlined above identified 21 patients with CDM.
Of the 24 patients excluded, 18 were excluded because initial
symptoms were clearly reported after the first month of life.
The remaining six patients were excluded due to symptoms
that were inconsistent with congenital onset, even when
recorded on the PIF as occurring within the first month.
In comparison, the CPSP is conducting active surveillance of incident cases that are identified through surveillance forms sent to more than 2500 paediatricians and
paediatric subspecialists monthly, with response rates of more
than 80%. A 94% response rate was achieved for completion
of follow-up clinical questionnaires. Patients identified in
this incidence study are recruited to participate in a five-year
natural history cohort focusing on developmental skills, quality of life, medical morbidity and mortality.
Ethics approval (University of Western Ontario, London,
Ontario) and approval from the US Registry Steering
Committee to examine anonymous information in the database were obtained. The study was funded by the William
Singeris National Centre for Myotonic Dystrophy Research
(London, Ontario). The information provided by the US
Registry in Microsoft Access (Microsoft Corporation, USA)
was re-entered into SPSS version 13 (SPSS Inc, USA) and
analyzed. Descriptive statistics were also analyzed using SPSS.
ReSultS
The 21 CDM cases included in the present study were born
between 1982 and 2003. The mean age at the time of registration in the database for patients was 9.4 years (range three to
24 years of age). Patients consisted of 13 males and
eight females. The majority of patients were Caucasian
(n=18), in addition to one of Hispanic or Latino ethnicity,
one African-American and one Asian. Most of the patients
were recruited to the registry via the Internet (n=10) or
through a muscular dystrophy association (n=6). Of the
21 patients registered, 13 (62%) had one other family member
in the US Registry. Eight patients (38%) were registered in
2002, three (14%) in 2003, six (29%) in 2004, three (14%) in
2005 and one (5%) in 2006. Due to confidentiality, the geographical distribution of cases could not be reported in the
results. The US Registry database administrators stated that
the northeastern states were over-represented. Regarding the
level of education, seven (33%) patients were in elementary
school, eight (38%) did not have any formal education and
six (29%) did not report an educational level. Occupational
information was collected and no patients reported employment; however, only two patients were of employment age.
diagnosis
Of the 21 patients, 18 cases reported diagnosis at birth or by
one year of age. The remaining three cases were diagnosed at
three, seven and 18 years of age. Although these latter cases
were diagnosed at a later age, all showed signs of weakness
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[US] Registry). The purpose of the US Registry is to establish
an anonymous database on DM and facioscapulohumeral
muscular dystrophy clinical and molecular information, and
to assist investigators in identifying and recruiting patients
into research trials. The US Registry’s database is derived
from patient-reported forms and retrospective analysis of
patient medical records. The second study, the Canadian
Paediatric Surveillance Program (CPSP) and natural history
cohort (7), aims to determine the incidence and outcome of
CDM. This study is specific to CDM and is a prospective
natural history cohort study with active surveillance (7). The
two studies have similar definitions of CDM; the CDM is
defined in the US Registry as an infant with facial or limb
muscle weakness in the first four weeks of life, and either
positive genetic testing or a mother with definite/probable
DM1, whereas the CPSP uses a definition of CDM based on
genetic diagnosis and symptoms requiring hospitalization for
more than 72 h in the newborn period.
The objective of the present study was to identify
patients with CDM in the US registry and to describe this
sample of patients. The US registry has one of the largest
collection of cases of CDM patients who have had their
symptoms verified and have undergone annual follow-up.
The discussion will highlight differences between the selfreport US registry and the CPSP.

Prendergast et al

Table 1
Symptoms in the neonatal period for 21 children with
congenital myotonic dystrophy

Table 3
Comorbidities reported on the patient information form for
21 children with congenital myotonic dystrophy

Symptoms

n

Medical condition

n

13

Constipation

6

Respiratory difficulties

4

Pneumonia

4

Swallowing problems

4

Gastroesophageal reflux

4

Bradycardia

1

Chronic infections

3

Cyanotic

1

Heart disease

2

Ptosis of the eye

1

Kidney problem

1

Torticollis

1

Chronic otitis media

1

Congenital diaphragm paralysis

1

Vesicoureteral reflux

1

Club feet

1

Encopresis and diarrhea

1

Failure to thrive

1

Some patients had more than one comorbidity indicated

Low muscle tone/floppiness

Some patients had more than one symptom indicated

Symptom

n

Weakness of face

17

Trouble speaking clearly

13

Difficulty walking on toes or heels or ankle weakness

12

Difficulty getting up from the floor, rising from a chair or
climbing stairs

11

Trouble with swallowing

10

Difficulty making a tight fist, loss of grip strength or
difficulty opening jars

7

Trouble with hands/grip locking up or hand stiffness

6

Racing heart beat, irregular heart beat, palpitations or
pacemaker

3

Trouble with breathing or shortness of breath

2

Baldness

1

Cataracts

0

Mean age of entry into the United States Registry was 9.4 years (range three
to 24 years)

within the first four weeks of life according to the PCL. Some
patients reported diagnosis by multiple physicians; however,
the majority of patients were diagnosed by a neurologist
(n=15 [71%]) and/or a specialist in a neuromuscular clinic
(n=9 [43%]). Only three (14%) were diagnosed by a primary
care physician, and none reported self-diagnosis.
A variety of diagnostic methods were used. By far the most
common method was genetic testing because 18 (86%)
patients reported having DNA testing performed. The medical
records of 14 patients submitted by their physician showed that
DNA testing was performed and also showed the associated
repeat size. The mean (± SD) CTG repeat size was 1528±411),
with a range of 940 to 2100. Two of the 21 patients reported
having both an electromyography and a muscle biopsy performed diagnostically, while one had electromyography only
and one other had a muscle biopsy only. Seven patients (33%)
reported receiving genetic counselling to understand more
about the familial nature of DM1.
Signs and symptoms
In the neonatal period, the signs and symptoms reported in
the US Registry are shown in Table 1. No data were
516

available to determine important birth characteristics such as
gestational age, Apgar scores, the resuscitative effort needed,
duration of neonatal admission, the need for assisted ventilation or feeding assistance. The symptoms reported by the
patients at the time of registration in the US Registry are
listed in Table 2. The mean age at registration was 9.4 years,
and ranged from three to 24 years of age.
Morbidity and mortality
More than one-half of the CDM patients reported gastrointestinal disturbance such as constipation (n=6 [29%]),
acid reflux (n=4 [19%]) and diarrhea (n=1 [5%]). Other
comorbidity problems included pneumonia (n=4 [19%])
and chronic infections (n=3 [14%]). Two patients reported
heart disease. Comorbidity data are presented in Table 3. Of
note, none of the patients reported having any of the following relevant medical conditions: diabetes, stroke,
asthma, thyroid problems, arthritis, stomach ulcers, sexual
dysfunction or psychological problems. No deaths were
reported in the database. Database administrators confirmed
that all patients available for follow-up were living at the
time of the present study.
The following medical assistive devices were needed:
wheelchairs (n=8 [38%]), ventilators (n=7 [33%]), continuous positive airway pressure or bilevel positive airway
pressure (n=7 [33%]), ankle braces (n=7 [33%]), long leg
braces (n=4 [19%]), walkers (n=2 [10%]) and canes (n=2
[10%]). No patient reported needing a cardiac pacemaker.
All 21 patients reported receiving physiotherapy, while
71% of patients reported receiving occupational and
speech therapy as well. One patient received vocational
rehabilitation, and none reported receiving psychological
counselling.
Sleep problems were assessed in the US Registry PIF by
the Epworth Sleepiness Scale (ESS) (8,9). The ESS ranges
from 0 (no daytime sleepiness) to 24 (severe sleepiness),
with scores greater than 10 indicating excessive daytime
sleepiness. ESS scores were available for 11 individuals with
CDM and showed a mean score of 7.1 (range one to 21).
Three individuals had scores of greater than 10, with one
individual (24 years of age) reporting a high chance of dozing
under all circumstances except for “sitting and talking to
someone”. Of the remaining patients, “watching television”
Paediatr Child Health Vol 15 No 8 October 2010
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Table 2
Symptoms at time of registration from the patient
information form for 21 children with congenital myotonic
dystrophy

CDM in the US Registry

(n=4) and “laying down to rest in the afternoon when circumstances permit” (n=3) were associated with a moderate
chance of dozing.

diSCuSSion
Examining the CDM cases in the US Registry provided a
description of one of the largest recent series of children
affected by CDM, in addition to demonstrating the feasibility of using the established US Registry for clinical research
in this population. The US Registry has allowed a review of
the clinical characteristics of 21 patients ranging from three
to 24 years of age, all of whom met the defined criteria for
CDM. As expected, all had some element of hypotonia at
birth; however, only six patients displayed neonatal respiratory problems or feeding dysfunction. Because hospitalization information was not specifically collected, it is unclear
whether these were sufficiently severe to require hospitalization. The symptom severity of this sample, however, is
indicated by the fact that 18 of 21 individuals required at
least one assistive device, with the majority requiring
devices such as wheelchairs, continuous positive airway
pressure or bilevel positive airway pressure. Furthermore, we
have demonstrated that a substantial amount of health care
resources are used by patients with CDM. The need for
health care resources is evidenced by the universal need for
physical therapy, and the need for speech therapy, occupational therapy and assistive devices in a majority of cases.
The lack of psychology intervention raises concern because
there is a high rate of attention-deficit hyperactivity disorder
and learning difficulties in children with CDM (10); it is
important for school-age children with CDM to be academically assessed to optimize their learning environment.
Furthermore, it is important to note that genetic testing confirmed the diagnosis in 85% of patients, yet only 33% reported
having genetic counselling to accompany the diagnosis,
which, given the autosomal dominant familial nature of this
disorder, is concerning because affected parents are at risk of
having more children with CDM and proper genetic counselling enables them to make informed reproductive choices.
No deaths were identified in registered patients or during
the follow-up period. Because the mortality from CDM has
been shown to be 25% in the first year of life (11), one
would expect some deaths in follow-up of the youngest children entered in the database. This observation may represent an ascertainment bias in the US Registry, given that
Paediatr Child Health Vol 15 No 8 October 2010
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longitudinal follow-up
Annual completion of the updated PIF includes between
one and three years of follow up. After the first year, there
was at least one update for 14 (67%) patients. These updates
were, in large part, updates on height and weight
(11 updates). Six updated the use of assistive devices and
four updated their grade in school. By the third year, eight
(38%) had at least one update; again, height and weight
were most reported (seven updates), with two school grade
updates. No data regarding the number of hospitalizations
were provided in the database.

parents may not register a child who is seriously ill or who
died early in the disease. Only one-third report having been
engaged in genetic counselling. Genetic counselling is a
critical aspect of the care in this population because there is
a high risk of CDM in future familial generations. Because
the onset of adult DM1 can manifest in mid-life, and in
certain cases with mild severity, the child presenting with
CDM is often the index case for the family (11). All families and individuals affected with DM1 should be referred
for genetic counselling, and then referred to a neuromuscular clinic for appropriate monitoring and management.
Overall, there was a low rate of comorbidity (diabetes, cataract, thyroid problems, orthopaedic problems and cardiac
abnormalities), which may further reflect ascertainment
bias or be due to the young age of the sample. Gastrointestinal
problems appeared most prominent, which is consistent
with the low tone effects of CDM on the musculature of the
gastrointestinal tract. Similarly, the lack of psychological
intervention raises concern that either these issues are not
reported accurately by caregivers or that patients are not getting appropriate services. There is a high rate of attentiondeficit hyperactivity disorder and learning difficulties in the
CDM population; it would be uncommon for a child of
school age not to have been assessed to optimize their learning environment. Finally, the lack of daytime sleepiness in
the sample was not expected, given the self-reported frequency of fatigue and somnolence of 81% reported in studies of childhood DM1 (12). However, the young age of most
patients might limit the appropriateness of the ESS in the
population.
The current organization of the US Registry offers
opportunities to those interested in performing clinical
research in CDM or even childhood-onset DM1, by
enabling informed patient selection and allowing personal
contact with registrants for participation in approved clinical studies. Providing a combined group of CDM and childhood DM1 registrants enabled the identification of CDM
cases using the current case definition; however, the US
Registry could, without difficulty, apply a clearer definition
of CDM to distinquish these subgroups.
Through comprehensive assessment of the acquired data,
it is evident that several data elements are not routinely collected by the US Registry, which may be important to comprehensively understand the clinical course of CDM.
Although the purpose of the US Registry is that of patient
identification for clinical studies, the addition of information regarding neonatal hospitalization (ie, need for a ventilator or feeding tube), developmental milestones and school
performance would help researchers more informatively identify subpopulations within the database and provide pilot
data to determine the necessity of certain studies in this
population. The US Registry requests that a referring physician’s note be submitted, which due to confidentiality is not
disseminated, and may provide additional information
regarding duration of hospitalization and interventions. The
inclusion of this clinical information would provide a further
level of verification, help to eliminate bias associated with

Prendergast et al

ReFeRenCeS

1. The new nomenclature and DNA testing guidelines for myotonic
dystrophy type 1 (DM1). The International Myotonic Dystrophy
Consortium (IDMC). Neurology 2000;54:1218-21.
2. Schara U, Schoser BG. Myotonic dystrophies type 1 and 2:
A summary on current aspects. Semin Pediatr Neurol
2006;13:71-9.
3. Harper PS. Congenital myotonic dystrophy in Britain.
I. Clinical aspects. Arch Dis Child 1975;50:505-13.
4. Hageman AT, Gabreels FJ, Liem KD, Renkawek K, Boon JM.
Congenital myotonic dystrophy; a report on thirteen cases and a
review of the literature. J Neuro Sci 1993;115:95-101.
5. Wesstrom G, Bensch J, Schollin J. Congenital myotonic dystrophy.
Incidence, clinical aspects and early prognosis. Acta Paediatrica
Scandinavica 1986;75:849-54.
6. Gonzalez de Dios J, Martinez Frias ML, Egues Jimeno J, et al.
[Epidemiological study of Steinert’s congenital myotonic dystrophy:
Dysmorphological characteristics]. Anales Espanoles de Pediatria
1999;51:389-96.

518

information, to understand the factors leading to attrition
on follow-up PIFs and to enquire whether these persons
would consent to clinical studies and under what circumstances. Additional studies may also involve sending questionnaires to parents and siblings of enrolled CDM patients
to enquire about the quality of life, developmental milestones, school performance, medical economics and other
management issues faced by these families. Finally, there is
potential to contact all adult members of the Registry to
better appreciate their experiences of CDM within their
immediate and extended families, and following up with
affected family members to enquire about neonatal care,
deaths and long-term therapies.
ConCluSion
CDM is a rare disease that requires considerable health care
resources to effectively manage a child in both medical and
psychosocial domains. The information presented adds to
the literature of CDM by offering a description of a large
cohort of children with CDM, and provides clinicians managing these children with a current understanding of the
clinical presentation and course of children with CDM.
Some limitations are identified in the US Registry, specific
to CDM, which become more evident in contrast with the
CPSP CDM program in Canada. Despite this, the US registry is a valuable resource for clinical research.
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patient recall and, thus, improve the accuracy of data submitted by a patient.
The ongoing, prospective CPSP and natural history study
of CDM (7) aims to determine the incidence of CDM, to
document the neonatal morbidity and mortality, and to
quantify the genotype-phenotype correlation in CDM.
Currently, the study has identified 31 incident cases since the
study inception in 2005. A mortality rate of 19% has been
noted in this cohort, with five of six deaths occurring within
the first month of life. Once the surveillance study is complete, these results will be published.
The greater number of incident CDM cases identified
through the initial four years of the CPSP initiative compared with the number of confirmed cases in the US
Registry may be due to the passive nature of recruitment of
the US Registry. Although it is well recognized that the
incidence of DM1 is highest in some Quebec regions (13),
this does not likely account for the difference. To improve
the breadth of enrollment in the Registry, it may be helpful
to create recruitment tools specifically aimed at enrolling
children in paediatric neuromuscular clinics and neonatal
intensive care units. An additional limiting factor in the
complete description of the natural history of the population in the US Registry is that follow-up information was
only available for eight of 21 individuals, which limits further understanding of the natural history in the US Registry
and raises questions about the feasibility of contacting individuals for research projects.
The US Registry clearly meets its objectives of enabling
rapid identification of patients with CDM and other forms
of DM for clinical research. Future steps will include contacting CDM patients to determine neonatal medical

